banner
FLT3 inhibitor G-749, Purity ≥98%
Inquiry

Cat. No.: X24-06-ZQ185

FLT3 inhibitor G-749, Purity ≥98%

Synonym: 1457983-28-6; FLT3 inhibitor; G749

  • MDL: MFCD28167815
  • CAS Number: 1457983-28-6
  • Compound CID: 78357765
img
Product Size
5 mg; 10 mg; 25 mg; 50 mg
Price
Datasheet
MSDS
Properties
Description
G-749, soluble in warmed DMSO and insoluble in water and ethanol, is a protein tyrosine kinase inhibitor that has shown potent biochemical activity against FLT3. It targets FLT3 (D835Y), Mer, Aurora B, AuroraC, Axl, c-Kit, FGFR1, FGFR3, FLT3, Fms, and IGF-1R.
Molecular Weight
521.41
Molecular Formula
C25H25BrN6O2
Targets
FLT3 (D835Y): 0.6 nM; Mer: 1 nM; AuroraB: 6 nM; AuroraC: 24 nM; Axl: 20 nM; c-Kit: 142 nM; FGFR1: 25 nM; FGFR3: 30 nM; FLT3: 0.4 nM; Fms: 19 nM; IGF-1R: >300 nM
Form
Lyophilized powder
Purity
≥98%
Solubility
Warmed DMSO: 22 mg/mL (42.19 mM); Water: Insoluble; Ethanol: Insoluble
Identity
Confirmed by NMR/HPLC/MS.
Applications
G-749 is used as a FLT3 inhibitor in cancer studies exploring its effects on disrupting leukemia cell signaling.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0